"Ethambutol" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863)
| Descriptor ID |
D004977
|
| MeSH Number(s) |
D02.092.782.258.368.265
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ethambutol".
Below are MeSH descriptors whose meaning is more specific than "Ethambutol".
This graph shows the total number of publications written about "Ethambutol" by people in this website by year, and whether "Ethambutol" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 10 | 11 |
| 2018 | 3 | 3 | 6 |
| 2019 | 2 | 3 | 5 |
To return to the timeline, click here.
Below are the most recent publications written about "Ethambutol" by people in Profiles.
-
Fluoroquinolones and isoniazid-resistant tuberculosis: implications for the 2018 WHO guidance. Eur Respir J. 2019 10; 54(4).
-
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study. J Antimicrob Chemother. 2019 10 01; 74(10):2994-3002.
-
Individualising therapy for drug-sensitive tuberculosis. Lancet Respir Med. 2019 10; 7(10):834-835.
-
Safety of pyrazinamide-including regimen in late elderly patients with pulmonary tuberculosis: A prospective randomized open-label study. J Infect Chemother. 2019 Dec; 25(12):1026-1030.
-
Severe disseminated tuberculosis in HIV-negative refugees. Lancet Infect Dis. 2019 10; 19(10):e352-e359.
-
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrob Agents Chemother. 2018 12; 62(12).
-
Regimen design and pharmacokinetic-pharmacodynamic science: lessons learned. Lancet Infect Dis. 2019 01; 19(1):3-4.
-
In Vitro MIC Values of Rifampin and Ethambutol and Treatment Outcome in Mycobacterium avium Complex Lung Disease. Antimicrob Agents Chemother. 2018 10; 62(10).
-
Accelerating Early Antituberculosis Drug Discovery by Creating Mycobacterial Indicator Strains That Predict Mode of Action. Antimicrob Agents Chemother. 2018 07; 62(7).
-
Mycobacterium marinum infections in Denmark from 2004 to 2017: A retrospective study of incidence, patient characteristics, treatment regimens and outcome. Sci Rep. 2018 04 30; 8(1):6738.